|
Mesothelioma
Treatment
Articles
and Abstracts
Gemcitabine
for malignant mesothelioma: A phase II
trial by the Cancer and Leukemia Group
B.
Lung
Cancer 2000 Feb-Mar; 31(2-3):311-7
Kindler
HL, Millard F, Herndon JE 2nd, Vogelzang
NJ, Suzuki Y, Green MR.
University
of Chicago Medical Center, 5841 S.
Maryland Avenue, Chicago, IL 60637, USA.
hkindler@medicine.bsd.uchicago.edu
PURPOSE:
The CALGB conducted a phase II multicenter
trial to evaluate the activity of
gemcitabine in malignant mesothelioma
(CALGB protocol 9530).
PATIENTS
AND METHODS: Seventeen patients were
accrued between February 1996 and May 1996
and received gemcitabine 1500 mg/m(2) by
intravenous infusion over 30 min weekly
for 3 weeks, followed by a 1 week break.
Eligibility included a performance status
of 0-2 by CALGB criteria, and no prior
chemotherapy. Nine patients had epithelial
cell type and eight had mixed or
sarcomatoid cell types. There were 11
cases with measurable disease and six with
evaluable disease.
RESULTS:
There were no complete or partial
responders. Eight patients had stable
disease, seven developed progressive
disease, and two were not evaluable for
tumor response. Two patients had minor
responses. Median survival from study
entry was 4.7 months (95% CI 3.1-12.9
months); one year survival was 24% (95% CI
10-55%). One patient remains alive at 37
months. There were two early deaths, one
from disease progression and one from
pneumonia. Toxicity was mild and included
anemia, lymphopenia and infection; no
patient experienced grades three or four
thrombocytopenia.
CONCLUSION:
No antitumor activity was observed for
single-agent gemcitabine in patients with
malignant mesothelioma in this multicenter
phase II study.
Publication
Types:
- Clinical
trial
- Clinical
trial, phase ii
- Multicenter
study
PMID:
11165412 [PubMed - indexed for
MEDLINE]
Click here to order or save
article
If
you have any questions regarding treatment
options or your legal rights, please
contact
us.
|